Hint mode is switched on Switch off
For swift navigation between sections

Neurocrine Biosciences
LEI 549300FECER0XBN49756

PDF download

Choose all Reset all
Download Cancel
Organization name
Neurocrine Biosciences, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Awards

News

01/08/2026 Neurocrine Biosciences (NASDAQ: NBIX) Shows Strong Financials and Strategic Growth
14/05/2026 Neurocrine Biosciences: Of The Original Report To Include The Audited Consolidated Financial Statements Of Soleno (as Defined In The Original Report) As Of And For The Year Ended December31, 2025 And To Include The Unaudited Interim Condensed Consolidated Financial Statements Of Soleno As Of And For The Three Months Ended March 31, 2026; And (ii)update The Information In Item 9.01(b) Of The Original Report To Include The Unaudited Pro Forma Condensed Combined Financial Information Of The Company, Consisting Of The Unaudited Pro Forma Condensed Combined Statements Of Income For The Six Months Ended June30, 2026 And The Year Ended December31, 2025. This Amendment No.1 Does Not Amend Any Other Item Of The Original Report Or Purport To Provide An Update Or A Discussion Of Any Developments At The Company Subsequent To The Filing Date Of The Original Report
14/05/2026 Neurocrine Biosciences: Entry Into A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Creation Of A Direct Financial Obligation Or An Obligation Under An, Regulation Fd Disclosure, Financial Statements And Exhibits
06/05/2026 Neurocrine Biosciences (NASDAQ: NBIX) Drives Growth with Strong Financials and Strategic Pipeline Expansion
05/04/2026 Neurocrine Biosciences: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
II q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300FECER0XBN49756
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0000914475
  • EIN
    33-0525145
Registration is required to get access.